TY - JOUR
T1 - A 24-week open-label extension study of memantine in moderate to severe alzheimer disease
AU - Reisberg, Barry
AU - Doody, Rachelle
AU - Stöffler, Albrecht
AU - Schmitt, Frederick
AU - Ferris, Steven
AU - Möbius, Hans Jörg
PY - 2006/1
Y1 - 2006/1
N2 - Background: This study is an extension of a 28-week, randomized, double-blind, placebo-controlled study of memantine in 252 patients with moderate to severe Alzheimer disease. Objective: To evaluate long-term memantine treatment in moderate to severe Alzheimer disease. Design, Setting, and Patients: Open-label, 24-week extension trial. Raters remained blind to the patients' initial study treatment. Patients (n=175) were enrolled from the previous double-blind study in an outpatient setting. Intervention: Twenty mg of memantine was given daily. Main Outcome Measures: Efficacy assessments from the double-blind study were continued and safety parameters were monitored. Results: Patients who switched to memantine treatment from their previous placebo therapy experienced a significant benefit in all main efficacy assessments (functional, global, and cognitive) relative to their mean rate of decline with placebo treatment during the double-blind period (P<.05). The completion rate for the extension phase of the study was high (78%) and the favorable adverse event profile for memantine therapy was similar to that seen in the double-blind study. Conclusion: These results extend previous findings that demonstrated the efficacy and safety of memantine in the treatment of patients with moderate to severe Alzheimer disease.
AB - Background: This study is an extension of a 28-week, randomized, double-blind, placebo-controlled study of memantine in 252 patients with moderate to severe Alzheimer disease. Objective: To evaluate long-term memantine treatment in moderate to severe Alzheimer disease. Design, Setting, and Patients: Open-label, 24-week extension trial. Raters remained blind to the patients' initial study treatment. Patients (n=175) were enrolled from the previous double-blind study in an outpatient setting. Intervention: Twenty mg of memantine was given daily. Main Outcome Measures: Efficacy assessments from the double-blind study were continued and safety parameters were monitored. Results: Patients who switched to memantine treatment from their previous placebo therapy experienced a significant benefit in all main efficacy assessments (functional, global, and cognitive) relative to their mean rate of decline with placebo treatment during the double-blind period (P<.05). The completion rate for the extension phase of the study was high (78%) and the favorable adverse event profile for memantine therapy was similar to that seen in the double-blind study. Conclusion: These results extend previous findings that demonstrated the efficacy and safety of memantine in the treatment of patients with moderate to severe Alzheimer disease.
UR - http://www.scopus.com/inward/record.url?scp=30344444750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=30344444750&partnerID=8YFLogxK
U2 - 10.1001/archneur.63.1.49
DO - 10.1001/archneur.63.1.49
M3 - Article
C2 - 16401736
AN - SCOPUS:30344444750
SN - 0003-9942
VL - 63
SP - 49
EP - 54
JO - Archives of Neurology
JF - Archives of Neurology
IS - 1
ER -